Community Guidelines
We welcome your comments and posts and look forward to a dialogue about science & health and our commitment to bring More Health to people around the world.
Search
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Sustainable Development - Our Commitment
Our Commitment
Horses
Horses
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
Fostering Science | Boehringer Ingelheim US
Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.
Heart Diseases
Heart Diseases
Poultry
Poultry
Our Science Focus
Our Science Focus
Innovation in CNS Disease Research
Innovation in CNS Disease Research
History
History
Fornovo San Giovanni (Bidachem)
Founded in 1981, Fornovo San Giovanni serves both – Human Pharma and Animal Health
Promising Phase II Results in Chronic Kidney Disease
Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease
Patient Safety & Pharmacovigilance at Boehringer Ingelheim
Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Contact Us
Contact Us
PetPro Connect: Veterinary Medicine in the Digital Age
Read more on PetPro Connect - the BI app & web portal, linking pet owners and veterinarians in a world transformed by digital health and new medicine.
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Ruminants
Ruminants
Retinal Diseases
Retinal Diseases
Rising Star Leads with Determination | Boehringer Ingelheim US
Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.
Corporate Profile
Corporate Profile
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
The Research Process
The Research Process